AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00855179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical to those containing Anstistax 360 mg
Study NCT03343444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
Description: Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
Study NCT03343444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
Description: Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
Study NCT01211938 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: single-fraction radiotherapy with concomitant 5FU and Hydrea
Description: single-fraction radiotherapy with concomitant 5FU and Hydrea
Study NCT01211938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiotherapy with concomitant Cetuximab
Description: hyperfractionated radiotherapy with concomitant Cetuximab
Study NCT01036139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649 (pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study NCT01036139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF2.649 (pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study NCT04084600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy Protocol
Description: Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
Study NCT04084600 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiotherapy Protocol
Description: Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
Study NCT02183610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BI 1356 as oral (p.o.) solution
Study NCT02183610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BI 1356 solution for i.v. infusion
Study NCT03510403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nastent™
Description: Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
Study NCT04005755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxigesic® IV
Description: acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
Study NCT03566316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Study NCT03566316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Study NCT03566316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT03566316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT03566316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT04338698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
Study NCT03358875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous injection (Anti-PD-1 monoclonal antibody)
Study NCT03358875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous injection (Antineoplastic, cytotoxic, taxane)
Study NCT03367962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-Ara-G
Description: the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
Study NCT04338698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
Study NCT04338698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir (75 mg orally twice a day for 5 days)
Study NCT04084600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Protocol
Description: Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
Study NCT04084600 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional Massage
Description: Traditional Massage is a gentle and superficial massage.
Study NCT04224831 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis
Description: Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment.
Study NCT01866215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose
Description: isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
Study NCT04338698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
Study NCT04451239 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: topical steroids and cyclosporin-A
Description: All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
Study NCT03768960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
Study NCT00838578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRN330
Description: KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
Study NCT00838578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
Study NCT03331003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level light therapy
Description: iRestore low-level light therapy on androgenetic alopecia
Study NCT03331003 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-LLLT wavelength group
Description: A LED light device is non-curative for the patients.
Study NCT01422317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA / DHA / Alpha-Tocopherol
Description: Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
Study NCT01422317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA / DHA / Alpha-Tocopherol
Description: Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
Study NCT01422317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corn Oil / Alpha-Tocopherol (4 mg)
Description: Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
Study NCT00461162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet DSMP
Description: Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
Study NCT00461162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face Dyspnea Self-management
Description: Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
Study NCT00461162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: 6 Monthly general health education classes and biweekly telephone calls from a health educator.
Study NCT04736420 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban dispensing claim is used as the exposure group
Study NCT04736420 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference group
Study NCT04352504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
Study NCT04352504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzel
Description: Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
Study NCT04925830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback; haemoncephalography biofeedback
Description: Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
Study NCT01908855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes
Study NCT01908855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes
Study NCT03991936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal saline intralesional injection
Study NCT03991936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 2.5 mg/mL
Description: 2.5 mg/mL intralesional injection
Study NCT00616798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 10mg po daily
Study NCT00616798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 30mg po daily
Study NCT00277810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR (SRA-333)
Description: one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
Study NCT00616798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 60mg po daily
Study NCT00727545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron bisglycine chelate
Study NCT00727545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT03461549 — intervention group
Intervention type: DEVICE
Intervention: Pressure and Temperature Sensor
Description: This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
Study NCT00616798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study NCT00616798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antipsychotic therapy
Description: As prescribed
Study NCT00616798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard antipsychotic therapy
Description: As prescribed
Study NCT02001220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre.
Study NCT02001220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At least twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
Study NCT00372151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Theanine
Description: 400 mg/day, caps.
Study NCT00372151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: caps.
Study NCT03887494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Implantation of Y-Strut + cementoplasty in the femoral neck
Study NCT05119348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPCOV
Description: Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
Study NCT03466255 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Contrast-enhanced ultrasound (CEUS)
Study NCT03874286 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Transplant
Description: Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
Study NCT00205803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Study NCT04314024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
Study NCT00193011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study NCT00193011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT00193011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate
Study NCT00193011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil
Study NCT02210988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Intervention with acupuncture
Study NCT03611816 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood taken
Description: Collection of clinical data
Study NCT03611816 — intervention group
Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of DNA
Study NCT03611816 — intervention group
Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of plasma
Study NCT03846427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib at a dose of 160 mg orally twice a day (BID)
Study NCT03991936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 5.0 mg/mL
Description: 5.0 mg/mL intralesional injection
Study NCT03991936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 7.5 mg/mL
Description: 7.5 mg/mL intralesional injection
Study NCT03991936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 10 mg/mL
Description: 10 mg/mL intralesional injection
Study NCT03931980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection
Description: we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
Study NCT03383250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal meal
Study NCT03394781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928
Description: oral suspension daily for 28 days
Study NCT03609502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral training
Description: the participants will be trained to perceive a non-native speech contrast
Study NCT01387594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: 2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
Study NCT01387594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: 1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
Study NCT04618549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach Hemiarthroplasty
Description: Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
Study NCT04618549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Posterior Approach
Description: Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
Study NCT04618549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral approach
Description: Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
Study NCT00916396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone
Description: 100 mg of DHEA a day (50 mg twice a day) for six weeks
Study NCT00916396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 mg of Placebo a day (50 mg twice a day) for six weeks
Study NCT03797885 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is administered to the participants for this study
Study NCT04655846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing intervention outcome: Breastfeeding Counseling (5244)
Description: Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding.
Study NCT04655846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nursing education about maternal care and usual education in maternity preparation course
Description: Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
Study NCT01319045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months